Novartis Licenses Worldwide Rights To Paratek's Broad-Spectrum Antibiotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Clarified regulatory path for antibiotics may have helped produce potentially lucrative deal for the private biotech.